top of page
  • Writer's pictureJeffrey White

Akumin - Time to Revisit

It is time to revisit Akumin ahead of the upcoming Q2 results and our participation in the CGF Growth Conference. 

Akumin Overview and Thesis - August 2020
Download • 472KB

Akumin will be releasing its Q2 2020 financial results on August 12th after market close and we will host a conference call/webcast at 8:30am EDT on Aug 13th. You can access the call by dialing 888-231-8191. There will also be simultaneous and archived webcast available at

Later that same day, CEO Riadh Zine will be presenting at the Canaccord Genuity Financial Growth Conference.  We already have a full schedule  of 1x1 institutional meetings (and excess demand!) as part of the conference schedule on Aug. 13th. 

Note that Akumin is now a US$125mm market cap (approx. $US250mm pre-COVID!) with an EV of over US$475mm.  2021 consensus revenue and EBITDA estimates of US$299.1 and US$76.3mm respectively. Based on 2021 consensus estimates, Akumin is currently trading at 6.1x EV/EBITDA, well below its closest peers, despite continuing to demonstrate higher growth and margins. 

The Akumin Overview and Thesis (link above) provides an updated overview that might be of interest.  It is obviously nothing official but is a good reminder of all the things Akumin has going for it. As an essential healthcare service, Akumin has weathered the disruption caused by COVID-19 extremely well!

For Q2, current consensus revenue and EBITDA estimates are US$46.0mm and US$1.1mm, respectively. 

It is a good time to refresh your thinking on the name…

Please let me know if you would like to discuss further or to try to coordinate a virtual meeting.

Jeffrey White

(416) 274-7762

16 views0 comments

Recent Posts

See All

Akumin Releases Q3 Results and 2022 Guidance

It has been a busy week at Akumin! There have been a number of important developments including: The release of our Q3 consolidated financial results on Dec 13th/21, which includes 1 month of combined


bottom of page